HMPL-453

Phase 2Small molecule

HHutchison Medipharma Limited

HMPL-453 is one of 88 small molecule programs targeting Malignant Mesothelioma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Malignant MesotheliomaActive, not recruiting

Intrahepatic CholangiocarcinomaActive, not recruiting

Malignant MesotheliomaPhase 2

Active, not recruiting

Intrahepatic CholangiocarcinomaPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

88 competitors in Intrahepatic Cholangiocarcinoma

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 2

11 2

Imfinzi

AstraZeneca

Phase 2

8 3

Eloxatin

Teva

Phase 2

2 4

Fudr

Pfizer

Phase 2

2 5

Pemazyre

Incyte

Phase 2

2 6

Rocaltrol

Alnylam Pharmaceuticals

Phase 2

1 7

Opdivo

Bristol-Myers Squibb

Phase 2

1 8

Abraxane

Bristol-Myers Squibb

Phase 2

1 9

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

9 10

Anlotinib Hydrochloride

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

Phase 2/3Recruiting

Intrahepatic Cholangiocarcinoma

NCT04353375

Clinical

Trials by Indication[1]

Advanced Solid Malignancies2 trials

A Study of HMPL-453 in Patients With Advanced Solid Malignancies

Unknown status·HHutchison Medipharma Limited·Phase 1/2·NCT03160833·33 enrolled

A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients With Advanced Solid Malignancies

Terminated·HHutchison Medipharma Limited·Phase 1·NCT02966171·14 enrolled

Advanced Solid Tumors1 trial

HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors

Unknown status·HHutchison Medipharma Limited·Phase 1/2·NCT05173142·141 enrolled

Malignant Mesothelioma1 trial

HMPL-453 in Advanced Malignant Mesothelioma

Unknown status·HHutchison Medipharma Limited·Phase 2·NCT04290325·27 enrolled

Intrahepatic Cholangiocarcinoma1 trial

HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma

Recruiting·HHutchmed·Phase 2/3·NCT04353375·235 enrolled

Unspecified1 trial

HMPL-453 Food Effect and PPI Study in Healthy Volunteer Study

Completed·HHutchmed·Phase 1·NCT05930119·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for HMPL-453. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HMPL-453 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HMPL-453. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hutchison Medipharma Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHutchison Medipharma Limited

HMPL-453

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2030

Trials by Indication[1]

Advanced Solid Malignancies2 trials

Advanced Solid Tumors1 trial

Malignant Mesothelioma1 trial

Intrahepatic Cholangiocarcinoma1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News